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Introduction 
Inhibition of the Androgen Receptor (AR) dependent reporter 
gene transcription provides an important piece of information that 
flags potential endocrine-disrupting effect of a wide range of chemicals, 
e.g. pesticides, industrial chemicals and drugs [1-4]. In vitro data for 
AR antagonism may be used for priority setting for further studies, e.g. 
in vivo experiments that are more costly and time-consuming. By use 
of QSAR models for AR antagonism the priority capacity is enhanced 
considerably and is further enhanced when the QSAR models and 
associated training sets are improved. Pesticides and industrial 
chemicals dominate in our existing QSAR model for AR antagonism 
[5]. It is well known that some drugs have AR antagonistic effect 
either as a primary mechanism of action for efficacy or as a secondary 
mechanism not directly involved in the pharmacological action of the 
drug [6-8].
A primary antiandrogenic effect of bicalutamide and flutamide is 
used in treatment of prostate cancer [6,9,10]. Secondary anti-androgenic 
effect is found for the diureticum spironolactone and probably also 
for the antiarrhytmics quinidine, procainamide, disopyramide, 
sotalol, amiodarone, ibutilide and dofitilide [4,7,8,11-15]. Several 
epidemiological studies have related statins to improvement of prostate 
cancer treatment [16-19]. Statins are also related to improvement of 
treatment of acne and Polycystic ovary syndrome (PCOS) [20,21] 
- diseases that involve high testosterone levels. Drugs with anti-
androgenic effect are known to be used against these diseases [6,22,23].
Spironolactone, quinidine, procainamide, disopyramide, 
sotalol, amiodarone, ibutilide, dofitilide and statins are well known 
Cardiovascular Disease (CVD) drugs [8,24]. An antiandrogenic effect 
of CVD drugs may thus be a possibility. Until now spironolactone is 
the only CVD drug present in the training set of our QSAR models 
for AR antagonism [4,5]. In this study our published QSAR model [5] 
was applied for analyzing the potential occurrence of AR antagonism 
among CVD drugs. 343 CVD drugs were screened. The QSAR model 
revealed biophores (chemical structures characteristic for active AR 
antagonism chemicals) in about 40% of the drugs. Chemical structures 
unknown to the QSAR AR antagonism model were also identified in 
40% of the CVD drugs (data not published). Therefore it was decided to 
analyze some of the CVD drugs for AR antagonism in the AR reporter 
gene assay described previously [4]. The purpose of this study was to 
identify new AR antagonisms among the CVD drugs and to extend 
the domain of the future AR antagonism QSAR models. The selection 
of CVD drugs for AR reporter gene assay is described in material and 
methods. 
Different QSAR models for AR antagonism have been published. 
Our QSAR model from 2008 was constructed by use of the software 
MultiCASE and 528 chemicals assayed by use of different cellular 
reporter gene assays [4]. Later, three modeling systems (MultiCASE, 
Leadscope and MDL QSAR) were used for the construction of AR 
antagonism models. There were 923-942 chemicals in the training 
sets also assayed by use of different cellular reporter gene assays [5]. 
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Abstract
For the development of QSAR models for Androgen Receptor (AR) antagonism, a training set based on reporter 
gene data from Chinese hamster ovary (CHO) cells was constructed. The training set is composed of data from the 
literature as well as new data for 51 cardiovascular drugs screened for AR antagonism in our laboratory. The data set 
represents a wide range of chemical structures and various functions. Twelve percent of the screened drugs were AR 
antagonisms; three out of six statins showed AR antagonism, two showed cytotoxicity and one was negative. The newly 
identified AR antagonisms are: Lovastatin, Simvastatin, Mevastatin, Amiodaron, Docosahexaenoic acid and Dilazep.
A total of 874 (231 positive, 643 negative) chemicals constitute the training set for the model. The Case Ultra expert 
system was used to construct the QSAR model. The model was cross-validated (leave-groups-out) with a concordance 
of 78.4%, a specificity of 86.1% and a sensitivity of 57.9%. The model was run on a set of 51,240 EINECS chemicals, 
and 74% were within the domain of the model. Approximately 9.2% of the chemicals in domain of the model were 
predicted active for AR antagonism. 
Case Ultra identified common alerts among different chemicals. By comparing biophores (alerts in positive 
chemicals) and biophobes (alerts in negative chemicals), it appears that chlorine (Cl) and bromine (Br) enhance 
AR antagonistic effect whereas nitrogen (N) seems to decrease the effect. A specific study of benzophenones and 
benzophenone derivatives indicate that a radical with a “high” number of atoms in 4-position and/or other positions 
generally decrease the anti-androgenic effect.
Citation: Jensen GE, Nikolov NG, Dreisig K, Vinggaard AM, Niemelä JR (2012) QSAR Model for Androgen Receptor Antagonism - Data from CHO 
Cell Reporter Gene Assays. J Steroids Horm Sci S2:006. doi:10.4172/2157-7536.S2-006
Page 2 of 10
J Steroids Horm Sci             Androgen Receptors                ISSN:2157-7536 JSHS an open access journal 
In addition, AR antagonism QSAR models based on only one single 
cell type and on a specific functional group, the brominated flame 
retardants (BFRs), have been published [25,26]. Recently, Kovarich 
et al. [27] used a training set consisting of AR antagonism data from 
24 BFRs in a QSAR model developed especially for prediction of 
BFRs. Osteosarcoma cells from human (U2 OS) were used in the AR 
antagonism assay.
AR reporter gene assays are based on different cell types, e.g. 
Chinese hamster ovary (CHO-K1) cells [4], human mammary 
carcinoma cells (MDA-kb2) [28], U2 OS cells [29], African monkey 
kidney cells (CV-1) [30], human prostate adenocarcinoma PC-3 
derived cell line (PALM) [31], human hepatoma liver cells (HepG2) 
[32] and yeast [33]. However, discrepancies between data from the 
different in vitro cell assays have been reported [34,35]. Previously 
it has been described that effectors which interact with the ligand-
receptor complex, like response elements, corepressor or coactivator 
proteins, or other transcription factors, are cell-type dependent [36]. 
In addition, Kojima et al. [37] reported low sensitivity of reporter gene 
assays based on yeast cells, HepG2 cells or Hela cells (cervical cancer 
cells) as compared to reporter gene assays based on CHO cells. Thus, it 
may be an advantage to use data from only one single cell type for the 
development of AR antagonism QSAR models. Our database for AR 
antagonism contains data from 1140 chemicals, data from around 900 
of these chemicals are based on CHO cells. As our AR antagonism data 
are collected continuously for all cell types, CHO cells are probably the 
most often used cell type for AR antagonism assays. Thus the aim of 
this study was to use AR antagonism data based exclusively on CHO 
cells to form a training set for a new “CHO” AR antagonism QSAR 
model. CHO data from an existing training set [5], new CHO data from 
the literature and new experimental data were used. 
New software for QSAR modeling is developed continuously. In 
this study a newly developed program, Case Ultra, from MultiCASE 
Inc. was used. The program is especially suitable for the unbalanced 
training set [38] that was used in this study.
Materials and Methods
In vitro AR Assay 
The AR antagonism assay was performed as previously described [4]. 
Shortly: Chinese hamster ovary cells (CHO-K1) were for each chemical 
run in two parallel lines; one transfected with the plasmids pSVAR0 
and MMTV-LUC for antagonism, and another transfected with the 
plasmids pSVAR13 and MMTV-LUC for the cytotox evaluation. The 
MMTV-LUC plasmid contains gene coding for the reporter enzyme 
Luciferase. The plasmid pSVAR0 contains gene coding for the human 
androgen receptor (AR). The plasmid pSVAR13 contains gene coding 
for AR without a ligand-binding domain (LBD). CHO cells transfected 
with pSVAR0/MMTV-LUC need R1881 for AR activation. CHO 
cells transfected with pSVAR13/MMTV-LUC are constitutively AR 
activated. The chemicals were tested at concentrations of 1, 3, 10, and 
30 μM, and within each assay all data were related to the response of 
0.1 nM R1881 (methyltrienolone), which was set to 100%. IC25, that 
is the concentration of test compound showing a 25% inhibition 
of the activity induced by 0.1 nM R1881, was calculated for each 
compound. The criteria for determining “a positive” was that a 25% 
inhibition of the 0.1 nM R1881-induced response should be reached at 
a non-cytotoxic concentration ≤10 μM. For QSAR modeling purpose, 
chemicals showing 25% inhibition at higher concentration than 10 μM 
belong to the group of “weak AR antagonisms/not AR antagonisms”, 
also referred to as negatives. 
Data for QSAR modeling
CHO data from literature: The data in the training set is comprised 
of experimental AR antagonism data from 15 publications [2-4,37,39-
49]. The data represents a wide range of chemical structures and various 
functions and covers natural hormones, synthetic hormones and 
drugs, pesticides, Polyaromatic hydrocarbons (PAHs), polychlorinated 
biphenyls (PCBs), brominated flame retardants (BFRs), plasticizers 
and plastic additives, food additives and cosmetics, antioxidants, plant 
compounds, roast mutagens and various industrial chemicals. The data 
originates primarily from our laboratory of the National Food Institute, 
the Technical University of Denmark (laboratory 1) [4,42,45,48,49], the 
laboratory of Hokkaido Institute of Public Health, Japan (laboratory 
2) [2,37,40,41,43] and the Endocrine Disrupting Chemical Analysis 
Center, Otsuka Life Science Initative, Otsuka Pharmaceutical Co. 
Ltd., 224-18 Ebisuno Hiraishi, Kawauchi-cho, Tokushima 771-0195, 
Japan (laboratory 3) [3,46]. Positive correlations were found between 
data from the various laboratories. Data reported (IC20(x) and IC50(y), 
respectively) from laboratory 2 and laboratory 3 found the equation: 
y= 3.589x + 0.3007 (R2= 0.6709, n=8), indicating an agreement with 
respect to potency between laboratories and a connection between 
IC-values usable as supplementary knowledge for grouping of the AR 
antagonism data.
All AR antagonism data were separated into two groups: a positive 
group (chemicals with IC25 ≤10 μM) and a negative group (chemicals 
with IC25 >10 μM or no activity).
Comparison of common data from the different laboratories 
showed a 83% (29/35)-91% (40/44) agreement. The compounds 
“2,4,5-trichlorophenoxyacetic acid” and “di-n-butyl phthalate” were 
indicated as weak AR antagonisms by Araki et al. [46] and this was 
in agreement with the finding in Vinggaard et al. [4], classifying the 
compound as negative. The remaining data was further evaluated. Some 
chemicals were excluded due to significant discrepancies between data 
without other supporting data (fenchlorphos, butyl benzyl phthalate, 
and the steroids estrone and corticosterone). Other data was excluded 
due to contradictory IC25/IC20 values close to 10 μM (fenvalerate, 
ethoxyquin). Laboratory 3 found IC50 values of 26.9 and 35.9 μM for 
4-tert-octylphenol and p-n-nonylphenol, respectively; according to 
laboratory 1, by using IC25 as the cut-off, these two chemicals were 
classified “AR antagonism, high” and “negative”, respectively. In the 
QSAR training set, 4-tert-octylphenol was set to positive and p-n-
nonylphenol to negative, also indicating that negative means either 
negative or weak positive. Takeuchi et al. [40] found the phthalate to be 
positive with an IC20 value of 4.8 μM. Due to more reports showing no 
AR antagonism, the di-n-butyl phthalate was included in the training 
set as a negative. In laboratory 3, dexamethasone was shown to have an 
IC50 value of 44.5 μM, but was estimated by laboratory 1 to have an IC25 
in the range of 1-3 μM (AR antagonism, moderate); the decision was 
taken to include dexamethasone in the training set as a positive. 
Benzophenones: Benzophenones represent a group of chemicals 
with functions as drugs and UV stabilizers in sunscreens, cosmetics 
and plastics [44]. Hydroxyl groups in benzophenones increase the 
antiandrogenic activity. The IC50 value for benzophenone was 77 μM 
and the calculated IC25 was 29 μM according to the reference [44]. Thus 
for the QSAR training set, benzophenone was classified as negative, 
while several of the hydroxylated benzophenone compounds were 
classified as positives [4,44]. 
Brominated flame retardants: BFRs are polybrominated diphenyl 
ethers and derivatives. In our previous QSAR model for AR antagonism 
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six BFRs analyzed by NFI were included in the training set [4,5]. New 
data from Kojima et al. [43] add further 15 BRFs to the training set. 
Analyzed by both laboratories (laboratory 1 and laboratory 2), BDE-
100 was found to be positive [4,43]. 
Cardiovascular drugs: 343 cardiovascular drugs were identified 
in Drug References [8,24], and predictions were made for these 
compounds by our AR antagonism QSAR model [5]. The predicted 
activity (pos, neg, out of domain) as well as the presence of biophores, 
deactivating fragments and unknown chemical fragments was noted 
down. For the selection of CVD drugs for experimental testing in 
in vitro assay and inclusion of data in the training set, the following 
criteria for the drugs were used:
•	 Possible AR antagonism according to the literature [11-21]
•	 Part of a drug group
•	 The presence of a biophore
•	 The presence of an unknown fragment
•	 Overall a distribution between positive and negative 
corresponding to about 25% and 75%, respectively; two times 
the presence of positives previously found for the EINECS 
chemicals [4,5].
100 drugs were selected due to these criteria. 51 of the drugs were 
directly commercially available and characterized as: 26 out of domain 
(QSAR predicted), 25 within domain with 7 positives and 18 negatives; 
40% of the drugs contained biophores and 40% contained unknown 
chemical fragments. Separated into pharmacological groups, the 
distribution was as follows, with the number given in parenthesis: Alpha 
blockers (1)*, angiotensin II receptor antagonisms (5), antiarrhythmics 
(17), lipid-regulating statins (6), lipid-regulating fibrates (5), lipid-
regulating nicotinates (1), lipid-regulating bile acid-binding resins 
(1), triglyceride-reducing polyunsaturated fatty acids (2), direct-acting 
vasodilators, (4), vasodilators for ischaemic heart disease (1), and 
Vasodilators for cerebral and peripheral vascular disorders (7).
*also belong to the direct-acting vasodilators. 
The whole process for the 51 selected CVD drugs, from QSAR 
prediction to in vitro laboratory experiments to the prediction by 
our new QSAR model, is described in Supplement 1. Supplement 1 is 
available at http://qsar.food.dtu.dk/AntiAndrogensup1.zip
Data preparation for QSAR modeling: For the QSAR modeling 
the chemical structures were described using SMILES (simplified 
molecular input entry system) and imported into OASIS DataBase 
Manager (DBM) [50]. In DBM, a hydrolysis simulation was performed 
and examination for chemicals without at least two carbons (including 
inorganics) and chemicals containing heavy atoms. Salts (e.g. sodium/
potassium-salts and hydrochlorides) were analyzed and the ones not 
containing toxic ions were processed by removing the ion part(s) from 
the structure. Duplicate or conflicting occurrences were removed from 
the structure set. Thereafter some SMILES codes were removed due to 
the MultiCase procedure for checking of SMILES and Data Kurator, 
the Case Ultra procedure for additional checking of SMILES for 
correctness.
During creation of the model, α hexachlorocyclohexane and β 
hexachlorocyclohexane were identified to have the same 2-D-structure 
(identical SMILES) and also having the same activity; only one was 
included in the training set. Dieldrin and Endrin were identified to 
having the same structure but different activities; none of them were 
included in the training set. 
The training set is available as supplement 2 at http://qsar.food.
dtu.dk/AntiAndrogensup 2.zip, and contains information on CAS 
numbers, machine-readable structure notations and activities.
Modeling methodology 
Algorithm: The Case Ultra 64-bit 1.4.0.0 modeling system from 
Multicase Inc. was used [38]. It is a further development of MC4PC, 
MultiCASE, previously used [4,5]. Case Ultra uses SMILES codes to 
enter chemicals. The program is a fragment (alert)-based statistical 
model system that aims to discover fragment combinations, which 
are relevant for the observed effect. Biophores are structural alerts that 
appear mostly in active molecules and therefore may be responsible 
for the observed activity. Case Ultra also looks at inactivities in the 
training set to identify deactivating fragments, deemed biophobes. 
Case Ultra has new functionalities and features and a new algorithm 
to discover structural alerts. New descriptors are added, e.g. estate 
values, surface and volume descriptors, Gasteiger atom based charges, 
vapor pressure, pKa and hydrogen bond donor/acceptors. Alerts are no 
longer only linear or with only one branch. They are now more general 
substructures. More model validation options exist, e.g. leave N% out 
N times, also for unbalanced training sets [38]. Case Ultra also uses 
physicochemical data (e.g. log (octanol/water) partition coefficient) 
as well as pharmacokinetic data (e.g. Lipinski rule of five and human 
intestinal absorption) and fragments as modulators (increasing or 
decreasing the activity prediction).
Applicability domain: While making a prediction, Case Ultra 
may report that the prediction is out of domain; this may be due to 
the presence of fragments not occurring in the training set. In the Case 
Ultra domain definition, up to one unknown fragment is accepted.
Predictions may also be inconclusive, e.g. when a chemical contains 
biophores as well as biophobes.
Statistical analysis: In Case Ultra a specific program for 
unbalanced training sets is available and used in this study. Leave-
groups-out cross-validation was used. The Case Ultra model was 
validated five times two-fold 50% cross-validation [38,51]. The cross-
validation result was evaluated by use of Cooper statistics [52]. Cooper 
statistics use sensitivity (ability to predict actives), specificity (ability to 
predict inactives), and concordance (overall accuracy) to describe the 
predictivity of a model. 
Results 
Cardiovascular drugs in the training set
Data of the newly assayed cardiovascular drugs are shown in table 
1. AR antagonism for drugs in concentration ≤ 10 μM was found in 
six drugs out of 51. This corresponds to AR antagonism in 12% of the 
investigated cardiovascular drugs. 
The initial QSAR prediction with our published MultiCase model 
[5] of 17 antiarrhytmics showed defitilide and ibutilide to be positive 
due to the presence of biophores. However, the molecules also contain 
deactivating fragments (biophobes). Only amiodarone among the 
antiarrhytmics contains solely a biophore. The in vitro assay showed 
that only amiodarone among the antiarrhytmics was positive. Among 
the lipid-regulating CVD drugs, two statins (lovastatin and simvastatin) 
out of six were predicted to be positive due to biophores only. These 
two statins were also found to be positive in the laboratory test. In 
addition, mevastatin was experimentally found to be positive. The 
QSAR prediction of atorvastatin, fluvastatin and pravastatin showed 
all three to contain biophores as well as unknown fragments. The in 
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vitro assay showed atorvastatin and fluvastatin to be cytotoxic, while 
pravastatin was negative (Figure 1). 
Among five lipid-regulating fibrates, only negative in vitro results 
were found. This was partly in agreement with the QSAR predictions 
Drug group Drug name CAS no. for QSAR analysis CAS no. for experimental assay Classification
Alpha blockers Tolazoline* 59-98-3 59-97-2 neg
Angiotensin II receptor antagonisms Irbesartan 138402-11-6 ª neg
Losartan 114798-26-4 ª neg
Valsartan 137862-53-4 ª neg
Telmisartan 144701-48-4 ª neg
Eprosartan 133040-01-4 ª neg
Antiarrhythmics Amiodaron 1951-25-3 ª AR antagonism, low
Disopyramid 3737-09-5 ª neg
Propafenon 54063-53-5 34183-22-7 neg
Sotalol 3930-20-9 959-24-0 neg
Flecainid 54143-55-4 54143-56-5 neg
Lidocain 137-58-6 ª neg
Mexiletin 31828-71-4 ª neg
Phenytoin 57-41-0 ª neg
Verapamil 52-53-9 152-11-4 tox
Hydroquinidine 1435-55-8 ª neg
Procainamide 51-06-9 614-39-1 neg
Quinidine 56-54-2 ª neg
Tocainide 41708-72-9 71395-14-7 neg
Bretylium 59-41-6 61-75-6 neg
Acecainide 32795-44-1 ª neg
Dofetilide 115256-11-6 ª neg
Ibutilide 122647-31-8 122647-32-9 neg
Lipid-regulating, statins Atorvastatin 134523-00-5 134523-03-8 tox
Fluvastatin 93957-54-1 93957-55-2 tox
Lovastatin 75330-75-5 ª AR antagonism, high
Pravastatin 81093-37-0 81131-70-6 neg
Simvastatin 79902-63-9 ª AR antagonism, high
Mevastatin 73573-88-3 ª AR antagonism, moderate
Lipid-regulating, fibrates Benzafibrat 41859-67-0 ª neg
Gemfibrozil 25812-30-0 ª neg
Ciprofibrate 52214-84-3 ª neg
Clofibrate 637-07-0 ª neg
Fenofibrate 49562-28-9 ª neg
Lipid-regulating, nicotinates Acipimox 51037-30-0 ª neg
Lipid-regulating, bile acid-binding resins Colestipo 37296-80-3 ª neg
Triglyceridereducing, Polyunsaturated 
fatty acids
Docosahexaenoic acid 6217-54-5 ª AR antagonism, low
Eicisapentaenoic acid 10417-94-4 ª neg
Vasodilators, direct-acting Diazoxide 364-98-7 ª neg
Hydralazine 86-54-4 304-20-1 neg
Minoxidil 38304-91-5 ª neg
Todralazine 3778-76-5 ª neg
Vasodilators, ischaemic heart disease Dilazep 35898-87-4 ª AR antagonism, moderate
Vasodilators, cerebral, peripheral vascular 
disorders
Buflomedil 55837-25-7 35543-24-9 neg
Cyclandelate 456-59-7 ª neg
Fasudil 103745-39-7 203911-27-7 neg
Ifenprodil 23210-56-2 ª neg
Inositol nicotinate 6556-11-2 ª neg
Nicotinyl alcohol 100-55-0 ª neg
Pentifylline 1028-33-7 ª neg
Pentoxifylline 6493-05-6 ª neg
*also a Vasodilator, direct acting 
Table 1: Cardiovascular drugs: The name and CAS number of each drug as well as the classification of the drug as positive (AR antagonism), negative or toxic are shown. 
The drugs were tested at 1, 3, 10, and 30 µM. Potency codes for positive drugs were as follows: high, 0.3 μM < IC25 ≤ 1 μM ; moderate, 1 μM < IC25 ≤ 3 μM ; low, 3 μM < 
IC25 ≤ 10 μM; neg, negative chemicals; tox, cytotoxic chemicals. Non-cytotoxic chemicals identified “low – high” were classified as positive for AR antagonism. For some 
drugs, two CAS nos. are given, one for QSAR use and one for the experimental assay, i.e. only non-salts versions of drugs are used for QSAR modeling. ªCAS no. identical 
with CAS no. for QSAR analysis.
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showing four out of the five drugs to be negative. Fenofibrate was 
predicted positive. QSAR prediction of two other lipid-regulating CVD 
drugs, acipimox and colestipol, showed acipimox to contain unknown 
fragments and colestipol to be negative. The in vitro assay showed both 
to be negative. 
Among the polyunsaturated fatty acids, the in vitro assay showed 
docosahexaenoic acid to be positive.
For two of the CVD drug groups, the “Angiotensin II receptor 
antagonisms” and the “Vasodilators, direct acting”, the QSAR 
prediction showed all (five and five, respectively) to be out of domain 
due to the presence of unknown chemical fragments. Four of the 
“Angiotensin II receptor antagonisms” also contained biophores. The 
in vitro assay showed all to be negative. Among the other vasodilators, 
the vasodilator used for ischaemic heart disease (dilazep) was QSAR 
predicted to contain solely biophores and was found to be positive in 
the in vitro assay.
Lovastatin, simvastatin, mevastatin, amiodaron, docosahexaenoic 
acid and dilazep were included in the QSAR training set as positives. 
The other drugs were included as negatives, except for the chemicals 
producing cytotoxicity (two statins, atorvastatin and fluvastatin, and 
one antiarrhythmic, verapamil), which were excluded from the training 
set. 
Data for 890 chemicals from the existing training set, new CHO 
data from the literature and the new experimental data for the CVD 
drugs made up for the new training set. These chemicals were reduced 
to 874 chemicals. Among the newly analyzed CVD drugs, acipimox 
and bretylium were not accepted during the technical adaptation 
procedure.
Validation, applicability domain and chemicals with 
antiandrogenic effect
The five times two-fold 50% cross-validation of the Case Ultra 
QSAR model (Table 2) showed a sensitivity of 57.9%, a specificity of 
86.1% and a concordance of 78.4%. 
In total, 51,240 discrete organic EINECS chemicals (European 
INventory of Existing Commercial chemical Substances) were 
predicted using the modeling system. Table 2 shows the domain of the 
Case Ultra model to be 74% of the EINECS chemicals. The percentage 
of the screened EINECS chemicals that were predicted positive for AR 
antagonism was 9.2%. 
Biophores 
From the 874 chemicals in the training set for the Case Ultra model, 
79 alerts were identified, 45 as biophores and 34 as biophobes. 35 of 
the biophores were present in three or more active molecules in the 
training set. Table 3 shows the most significant alerts in the training set 
of the Case Ultra model; in addition, other alerts were shown. The most 
significant alerts (Alert no. 6 (cc(ccc)c ) and alert no. 1 ((Cl)ccccc)) 
were primarily found in PCBs. Other alerts, e.g. no. 4 (c1ccccc1), were 
found in PCBs and chemicals from other groups (e.g. brominated 
diphenyl ethers) as well. 
Biophore no. 15 (c(O)cccc(O)) was found solely in benzophenones. 
Benzophenones with the hydroxyl group in 2-position contain biophore 
no. 15. Another biophore (no. 5, (c(c(ccc)=O)C ) was found in other 
benzophenones as well as in other chemicals. Although experimentally 
negative benzophenone contains alert no. 5 (17 out of 23 molecules 
containing this alert are active). In addition, benzophenone also contains 
a deactivating fragment (alert no. 75(c1(C(c2ccccc2))ccccc1, 0 out of 2 
molecules containing this alert are active). The negative hydroxylated 
B: Cytotoxic : (d) Fluvastatin, CAS no 93957-54-1; (e) Atorvastatin, CAS no 134523-00-5. 
B:  Negativ: (f) Pravastatin, CAS no 81093-37-0. 
Figure 1: The AR antagonism of statins shown by use of the experimental in vitro assay.  (a) Positive: a: Mevastatin, CAS no 73573-88-3; (b) Simvastatin, CAS no 79902-
63-9; (c) Lovastatin, CAS no 75330-75-5.
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benzophenone derivatives containing alert no. 5 were characterized 
by having a radical with a “high” number of atoms in 4-position and/
or other positions, e.g. octyloxy, sulfonic acid, dibutylamino and 
2-methylpropanoic acid 1-methylester. The CVD drug fenofibrate 
belongs to this group of negative benzophenone derivatives and also 
contains a deactivating fragment (alert no. 64 (Cc1ccccc1O) 0 out of 7 
molecules containing this alert are active) (Figure 2).
Alert no. 12 (ccc(cc)c) was mostly found in PAHs with a distribution 
between positive and negative of 75%.
Alert no. 13 (cccc(O)c ) was present in two of the new identified 
AR antagonisms with cardiovascular drug effect (amiodarone - 
an antiarrythmics, and dilazep - a vasodilator used for treatment 
of ischaemic heart disease). Other chemicals with this alert were 
herbicides, fungicides and BRFs. Figure 3 shows alert no. 13 in 
prochloraz (a fungicide), BDE-100 (a BFR) and amiodarone (a CVD 
drug). Distribution between positive and negative chemicals in this 
alert group was 75%. 
The three active statins contained a common alert (no. 27), an 
alert not found in other types of chemicals; the alert contained a high 
number of carbons (16) and oxygen (5). However, as in the initiating 
MultiCASE QSAR prediction, lovastatin and simvastatin differ from 
mevastatin; in addition, lovastatin and simvastatin contained biophore 
no. 33 also found in 3-methylpent-1-ene and 1-hexene,3 methyl. 
Mevastatin also contained an additional alert (no. 26), an alert which 
was common with spironolactone, betulin, corticosterone acetate and 
mifepristone, all steroid-like drugs. For the last new drug with AR 
antagonistic effect “Docosahexaenoic acid”, the alert was the whole 
molecule. 
Deactivating fragments (Biophobes)
Table 4 shows the alerts in the inactive chemicals (the biophobes). 
Nitrogen is present in four out of ten most significant biophobes, two 
in ring structures. Sulfur and phosphorus were present in one alert 
each; otherwise carbon atoms and oxygen make up the alerts. The 
most significant biophobe was alert no. 46 consisting of a nitrogen-
carbon structure ([n]c) placed in ring structures, 57 out of 58 molecules 
containing [n]c are inactive. Among the CVD drugs, all five Angiotensin 
II receptor antagonisms contain alert no. 46. In addition, three other 
of the CVD drugs also contained alert no. 46. Alert no. 47 consists of 
the hydroxylated part (CO) of organic acids, 51 out of 54 molecules 
containing (CO) are inactive. Many of the inactive cardiovascular 
drugs contribute to the training set with molecules containing alert 
no. 47. However, the two mentioned polyunsaturated fatty acids 
experimentally found to be AR antagonists (docosahexaenoic acid and 
γ-linolenic acid) also contain alert no. 47. 
*chemicals predicted marginal or inconclusive are not included
Table 2: The CHO AR antagonism model applied to 51,240 EINECS chemicals.
Software Chemicals accepted by the modeling system Chemicals in domain* Chemicals in domain with AR antagonism activity
Number (%) Number (%) Number (%)
Case Ultra 45,511 (100) 33,715 (74) 3,090 (9.2)
ªstructural alerts are described using SMILES notation for aliphatic and aromatic compounds according to the Daylight Theory Manual [59]. Notation: Lower case atoms 
are aromatic. 
( ): branch point. When the alert covers part of an aromatic structure, the attached part of the alert (aliphatic or aromatic) is enclosed in parenthesis.
btwo occurrences of the same biophore in the mentioned molecule.
c(1-p-value) x 100
Table 3: The most significant alerts (biophores) and the alerts in the active CVD drugs in the Case Ultra AR antagonism model.
Biophores Example of a molecule containing the alert and main chemical group
Statistical 
significancec
Molecules containing alerts 
no Structural alertª Chemical name/                     main chemical group CAS no. % total active inactive
6 cc(ccc)c 2,3',4,4',5-Pentachlorobiphenyl/ Biphenyls 31508-00-6 100 18 17 1
1 (Cl)ccccc Dichlofenthion/   polychlorbiphenyls 97-17-6 99.8 35 26 9
15 c(O)cccc(O) 2,4-Dihydroxybenzophenone/ Benzophenones 131-56-6 99.6 8 8 0
2 c(Clccc)ccClb 2,2',3',4,4',5-Hexachlorobiphenyl/ polychlorbiphenyls 35065-28-2 99.7 26 20 6
3 (Br)ccc
O-(4-Bromo-2,5-dichlorophenyl) O-methyl 
phenylphosphonothioate/ Brominated diphenyl 
ether
21609-90-5 99.5 25 19 6
4 c1ccccc1b 2,3,3',4,4'-Pentachlorobiphenyl/ Brominated diphenyl ether, polychlorbiphenyls 32598-14-4 99.5 25 19 6
7 c(cc)cc 2,3',4,4'-Tetrachlorobiphenyl/ Biphenyls 32598-10-0 99.5 20 16 4
5 Ccc(C(=O)cc)ccb Chlorohydroxy benzophenone/ benzophenones  85-19-8 98.8 23 17 6
8 Cc1ccccc1 4-(1,1,3,3-Tetramethylbutyl)phenol/ methylbenzene 140-66-9 97.8 19 14 5
10 cc(OP(=S)O) Dichlofenthion/Phosphorbenzene 97-17-6 96.7 18 13 5
11 (Cl)ccc(Cl) 2,4,6-Trichlorophenylhydrazine/ chlorbenzene 5329-12-4 96.7 18 13 5
12 ccc(cc)c 7,12-Dimethylbenz(a)anthracene/ PAHs 57-97-6 95.8 15 11 4
13 cccc(O)c Amiodaron/no main chemical group, structure: oxygen linked to ring structure
1951-25-3 94.6 12 9 3
27 * Mevastatin 73573-88-3 87.5 3 3 0
*c(=o)occ2c(=c)ccc2CCc1cc(O)cc(=O)o1
26 ccc(c( C )) Mevastatin 73573-88-3 84.4 5 4 1
33 CC( C )C Simvastatin 79902-63-9 75.0 4 3 1
Citation: Jensen GE, Nikolov NG, Dreisig K, Vinggaard AM, Niemelä JR (2012) QSAR Model for Androgen Receptor Antagonism - Data from CHO 
Cell Reporter Gene Assays. J Steroids Horm Sci S2:006. doi:10.4172/2157-7536.S2-006
Page 7 of 10
J Steroids Horm Sci             Androgen Receptors                ISSN:2157-7536 JSHS an open access journal 
Discussion
The CVD drugs and the AR antagonism
The in vitro assay showed an occurrence on 12% of AR antagonisms 
among cardiovascular drugs. This is at the level previously found 
among 49,292 EINECS chemicals [5]. However, as for the EINECS 
chemicals, some drug groups contain AR antagonisms more frequently 
than others. Among the antiarrhytmics only amiodarone was positive. 
The presence of antiandrogenic effect among statins was confirmed. 
An intuitive evaluation of figure 1 indicates that the AR antagonism 
activity of statins may be related to the pyran part and the cytotoxicity 
to the azole, benzene fluoride part. The presence of antiandrogenic 
effects of statins and not of fibrates and acipimox and colestipol are 
supported by the findings in a Finnish epidemiological study. This 
study showed statins to have a beneficial effect on prostate cancer 
prevention; this effect was not found for fibrates, acipimox and 
colestipol [19]. The finding of docosahexaenoic acid as positive was 
unexpected, but another polyunsaturated fatty acid “γ-linolenic acid” 
was also found to be positive in a previous study [4]. The vasodilator 
used for ischaemic heart disease (dilazep) was also found to be positive. 
This in vitro finding was expected only due to the prediction by our 
published QSAR model [5]. This study shows that CVD drugs that 
were predicted to be positive by our previous published QSAR model 
were generally confirmed to be positive in the in vitro assay.
The new QSAR model
The concordance of 78.4% was slightly higher than the concordances 
of our previous QSAR models for AR antagonism [4,5]. Modeling the 
newly developed training set by use of the MultiCASE software, which 
we have used for previous QSAR modeling [5], a similar concordance 
on 78.7% was found. The domain of the present Multicase Ultra model 
was improved from about 60% to 74% as compared to our previous AR 
antagonist QSAR models [4,5].
Alerts (biophores/biophobes) and the CVD drugs
In some cases, an individual alert can make up the main part of a 
chemical group, e.g. PCBs or benzophenones, but can also be common 
for chemicals belonging to different chemical groups. PCBs which in 
particular are AR antagonists (74% of 39 PCBs was experimentally 
shown to be AR antagonists [4]) does not have common biophores 
with the CVD drugs in this study. 
Evaluating positive and negative chemicals in the alert groups it was 
found that a radical with a ”high” number of atoms in 4-position or/and 
other positions may decrease the AR antagonism of benzophenones. 
The CVD drug fenofibrate contains the actual biophore but also a 
radical with a ”high” number of atoms in 4-position and a significant 
biophobe and  perform no AR antagonism.This finding adds new 
knowledge to the identification of chemical structures of importance 
for the AR antagonism of Benzophenones. Kowamura et al. [44], has 
previously shown that a hydroxylated group at the 2-position generally 
enhances the antiandrogenic activity of benzophenones (Figure 2). 
Thus evaluating positive and negative chemicals in the alert groups 
of QSAR models may be a useable supplementary tool for potency 
evaluation.
Alert group no. 13 (cccc(O)c ) was present in chemical groups with 
different functions, e.g. prochloraz (a fungicide), BDE-100 (a BFR) and 
amiodarone/dilazep (CVD drugs). This illustrates that it is valuable to 
include a wide range of chemical structures in the training set (Figure 
3).
The three statins performing AR antagonism were present in one 
alert group (no. 27). This biophore contained the pyran part (Figure 
1). Lovastatin/simvastatin and mevastatin were also included in an 
additional biophore group, respectively. Mevastatin was in the same 
biophore group as steroid-like drugs, e.g. spironolactone. The statin 
with no AR antagonism “Pravastatin” was in the large alert group 
ªstructural alerts are described using SMILES, see footnote to Table 3. b(1-p-value) x 100
Table 4: The most significant alerts (biophobes) in the inactive molecules and the alerts in the inactive CVD drugs and benzophenone in the Case Ultra AR antagonism 
model.




Molecules containing alerts 
no Structural alertª Chemical name/ main chemical structure CAS no. % total active inactive
46 [n]c Hydralazine/                     nitrogen containing 
ring structure
86-54-4 100 58 1 57
47 CO Pravastatin/               hydroxylated compounds 
in acids
81093-37-0 100 54 3 51
48 cc(=O)c Benzanthrone/unsaturated oxygen linked to ring 
structure
82-05-3 100 35 0 35
49 S(=O)=O Sulfanilamide/                      sulfon compounds 63-74-1 100 37 2 35
50 CCCCCC Hexyl cinnamic aldehyde/     lineaer saturated 
carbon structure
101-86-0 100 34 2 32
51 ccn Quinoline/                         nitrogen in ring 
structure
91-22-5 100 26 1 25
52 (c(O)cc)o Quercetin/hydroxylated compounds linked to 
benzene
117-39-5 100 26 2 24
53 C=N, c=n Tolazoline/unsaturated nitrogen, carbon in 
aromatic as well as aliphatic structure
59-98-3 100 23 1 22
54 cc(cC)cc p-Toluenesulfonamide 70-55-3 100 23 2 21
55 P=O Trichlorofon/unsaturated phosphor, oxygen 
linear structure
52-68-6 100 19 0 0
56 ccc(N)cc 1-Naphthylamine, N-phenyl-/     N-phenyl 90-30-2 100 19 2 17
59  c(C(=O)N) Flecainide 54143-55-4 100 13 0 13
61 cCc Ifenprodil 23210-56-2 99.7 12 1 11
64 Cc1ccccc1O Fenofibrate 49562-28-9 99.2 7 0 7
75 c1(C(c2ccccc2))ccccc1 Benzophenone 119-61-9 75 2 0 2
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not accepted due to the technical procedure, were predicted to be out 
of domain. 
Case Ultra makes use of the ratio between active/inactive when 
predictions are made and chemicals like fatty acids with unexpectedly 
AR antagonistic activity would probably be predicted as inactive 
AR antagonisms, not least due to the biophobe no. 47. Only one 
biophore will exist for such chemicals and cover the whole molecule. 
Thus, in spite of having QSAR models for important priority setting, 
experimental measurement should be performed when possible. The 
AR antagonism of docosahexaenoic acid and γ-linolenic acid [4] is a 
good example of this. This property of these unsaturated fatty acids 
deserves further attention. 
By comparing biophores and biophobes it appears that chlorine 
(Cl) and bromine (Br) enhance the AR antagonistic effect while 
nitrogen seems to decrease the effect.
Comparison of AR antagonism data between assays based on 
different cell types
In general, a good agreement exists between qualitative data 
from various AR reporter gene assays, and QSAR models have 
been developed by use of data from different assays [4,5]. Minor 
disagreements between data for AR antagonism in CHO cells and U2-
OS cells are found [4,29,43]. A comparison of AR antagonism data for 
brominated flame retardants experimentally performed on U2-OS cells 
as well as on CHO cells shows a possible disagreement on 27% (3/11), 
i.e. differences were found for BDE-153, BDE-190 and TBBPA.
Disagreement between AR antagonism in CHO cells and MDA 
(human mammary carcinoma) cells was also found; i.e. chemicals 
with AR antagonism in CHO cells were inactive in MDA cells with 
steroids dominating, making up three (progesterone, cyproterone 
acetate and 17β-estradiol) out of four chemicals [4,28,53]. The fourth 
chemical was chlordane [2,34,54]. This disagreement for chlordane 
was also reported previously by Aït-Aïssa et al. [34]. For chemicals 
showing AR antagonism in MDA cells but inactive in CHO cells, all 
were non-steroids (phenanthrene, pirimiphosmethyl, chlorpropham, 
metolachlor, pretilachlor) [2,4,28,34,55]. Chemicals like diethyl 
phthalate, aldrin and γ-lindane having IC50 values at concentrations of 
60 - 80 μM in MDA cells were negative in CHO cells [4,28,40] where 
the cut-off for positive results was set at 10 μM. However, due to the 
relatively high concentration needed for AR antagonism in MDA cells, 
these chemicals were considered negative in the two cell assays.
Thus, discrepancies in AR antagonism between cellular assays 
should without a doubt be taken into account when QSAR models are 
to be developed. Data from some cell types seem more appropriate to 
include in the same training set than others, without exclusion of too 
many contradicting results. Individual cellular QSAR models as well 
as multicellular QSAR models for AR antagonism could be developed 
with advantage.
Discrepancies in AR antagonism between cells may be due to 
difference in mechanism as well as the used cell type. Differences 
may be: initiating ligands (R1881, DHT) for the AR, metabolism, 
reporter plasmid, cellular presence of endogeneous receptors (AR, 
glucocorticoid receptor (GR)), cytotoxicity (transcription complex 
level (used in CHO assays), use of phase-contrast microscopy for 
cellular vacuolization (in MDA assays), etc.) [2,4,28,55]. 
In addition, discrepancies in AR antagonism between cells may 
be due to chemical specific capacity for agonism and Luciferase 
Figure 2: The AR antagonism of Benzophenone and Benzophenone 
derivatives. The effect of hydroxylation and radical substitution is illustrated. (A) 
Benzophenone - a weak AR antagonism, (B) 4-hydroxy-4’-chlorobenzophenone 
- a strong AR antagonism, (C) Fenofibrate - no AR antagonism. 
Figure 3: A common biophore (alert no. 13 ( cccc( O ) c ) in chemicals with 
different primary functions. (A) a fungicide (Prochloraz, CAS no. 67747-09-5), 
(B) a brominated flame retardant (BDE-100, CAS no. 189084-64-8) and (C) a 
drug (Amiodarone, CAS no. 1951-25- 3), respectively. The common biophore 
is marked. 
no. 47 (CO), strongly indicating no AR antagonism. Using our new 
QSAR model on the experimentally cytotoxic statins fluvastatin and 
atorvastatin, the prediction showed both to be “inconclusive” due to 
content of biophores as well of biophobes. Acipimox and bretylium, 
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inhibition [3,45,56-58]. AR agonists are very rare among industrial and 
environmental chemicals (2/502 =0.5%) [2,3,39,43,44,47], but may be 
rather related to the steroid structure [3,35].
Deviations between data from different CHO assays may also 
occur. This may be related to minor differences between protocols. 
Thus some laboratories use R1881 to initiate the AR mediated 
transcription, other laboratories use DHT. Some laboratories report 
IC25 and measure inhibition up to 10 μM; other laboratories report IC50 
and measure inhibition up to 100 μM or higher. Compared to other 
cellular AR antagonism protocols, the applied assays in the CHO assays 
for cytotoxicity seem relatively similar, i.e. the cytotoxicity of chemicals 
is evaluated by transcriptional activity [2,4], which is the ideal way to 
investigate cytotoxicity in this context.
Conclusion
In the development of QSAR models for Androgen Receptor 
(AR) antagonism, a training set based on Chinese hamster ovary 
(CHO) cells was constructed. Data from the literature and data on 
51 cardiovascular drugs recently screened for AR antagonism at our 
laboratory at the National Food Institute (NFI) make up the training 
set. All data together represent a wide range of chemical structures 
and various functions. Twelve percent of the NFI screened drugs 
are AR antagonisms; 3 out of 6 statins showed AR antagonism, two 
showed cytotoxicity and one was negative. Newly identified AR 
antagonisms are: Lovastatin, Simvastatin, Mevastatin, Amiodarone, 
Docosahexaenoic acid and Dilazep.
A total of 874 (231 positive, 643 negative) chemicals constitute the 
training set for the model. The Case Ultra expert system was used to 
construct the QSAR model. Case Ultra showed a concordance of 78.4%, 
a sensitivity of 57.9% and a specificity of 86.1%. The model was run on 
a set of 51,240 EINECS chemicals, and 74% were within the domain of 
the model. Approximately 9.2% of the chemicals in the model domain 
were predicted active for AR antagonism. 
Case Ultra identifies common alerts among chemical groups 
with equal as well different functions. By comparing biophores and 
biophobes, it appears that Cl and Br may enhance AR antagonistic 
effect while nitrogen seems to decrease the effect. A specific study of 
benzophenones and benzophenone derivatives indicate that a “high” 
number of atoms in 4-position and/or other positions generally 
decrease the antiandrogenic effect.
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